Linda Bain (AUTL) details multiple Autolus stock option grants and vesting
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Autolus Therapeutics plc director Linda Bain filed an initial ownership report showing multiple option awards over American Depositary Shares. The holdings include options over 105,000 ADSs at an exercise price of 2.3800, 80,000 ADSs at 3.4800, and additional grants with exercise prices up to 30.2400. Footnotes indicate one option is fully vested and exercisable, while another vests in twelve equal monthly installments commencing on July 26, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Bain Linda
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 31,397 shares (Direct)
Footnotes (1)
- Fully vested and exercisable. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.
FAQ
What does Linda Bain’s Form 3 for Autolus Therapeutics (AUTL) disclose?
The Form 3 discloses that director Linda Bain holds several stock options over Autolus Therapeutics American Depositary Shares. It lists each option’s exercise price, expiration date, and underlying share amount, providing a snapshot of her derivative equity position as of the reporting date.
How many Autolus Therapeutics ADSs are covered by Linda Bain’s largest option grant?
The largest reported option grant covers 105,000 American Depositary Shares with an exercise price of 2.3800 per share. Other grants cover 80,000 and 20,000 ADSs at lower and higher exercise prices, giving her a range of potential equity exposure across several future expiration dates.
Are any of Linda Bain’s Autolus Therapeutics options already vested and exercisable?
Yes. A footnote states that one option is “fully vested and exercisable”, meaning all underlying ADSs can be purchased at the stated exercise price. Another option is scheduled to vest in twelve equal monthly installments starting on July 26, 2025, increasing her exercisable position over time.
When do Linda Bain’s Autolus Therapeutics option grants expire?
The disclosed options have staggered expiration dates running from June 21, 2028 through June 26, 2035. Each grant lists a specific expiration date, so the rights to buy the underlying American Depositary Shares must be exercised, if at all, before those respective deadlines.
What vesting schedule is described for one of Linda Bain’s Autolus options?
One option is described as vesting in twelve equal monthly installments beginning on July 26, 2025. This means the right to purchase the underlying American Depositary Shares increases each month over a one-year period, creating a gradual build-up of exercisable options rather than a single cliff vest.